ProEthic starts PRO-513 Phase III

ProEthic (Montgomery, Ala.) started the double-blind, placebo-controlled Phase III IMPACT trial of PRO-513 to treat migraine headaches. The co-primary endpoints of the North American trial in 650 pati...